Recent Public Health press releases & news

 [PRESSWIRE] PALO ALTO, Calif., June 19, 2019 -- Vynca, the nation's leading advance care planning solution, announced today that it has secured $10.3 million in Series B funding from First Trust Capital Partners, OCA Ventures, and Spectrum Health Ventures, in addition to key strategic individual investors.

[PRESSWIRE] Budapest - June 13, 2019 -- Historically, the number of RCTs performed in the ESRD population has been very low compared to other medical subspecialties. Furthermore, several of the few large RCTs conducted in patients with ESRD have yielded inconclusive or negative results, dampening enthusiasm for future investment in similar trials.

[PRESSWIRE] Budapest - June 13, 2019 -- High cardiovascular morbidity and mortality remain a persisting problem in patients with CKD. Many efforts have been made in subjects with normal kidney function to prevent and to reduce the progression of cardiovascular diseases.

[PRESSWIRE] Budapest - June 13, 2019 -- Alport syndrome (AS) is a hereditary type IV collagen disease that leads to progressive proteinuria, renal fibrosis, and kidney failure.

 [PRESSWIRE] NEWARK, Del., June 12, 2019 -- Laurel Bridge Software, a provider of software solutions that enable health systems to automate and centrally manage their medical imaging workflows, announces their participation in the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting in Aurora, CO, June 26 – 28.

 [PRESSWIRE] LAGUNA HILLS, Calif. - May 1, 2019 -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, will present interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled "Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS", at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Dallas, TX.

[PRESSWIRE] Parma - April 26, 2019 -- The recently published CREDENCE study [1] showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. The study results were presented at the World Nephrology Congress in Melbourne and showed that Canagliflozin was associated with a 34% risk reduction of the renal end point (end stage renal disease, doubling of serum creatinine or renal death). The previous day, the SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%).

 [PRESSWIRE] SAN JOSE, Calif., March 21, 2019 -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering. The gross proceeds of the offering are expected to be approximately $3.9 million.

[PRESSWIRE] Parma – 18 April 2019 -- Kidney transplantation is the best renal replacement therapy available. Although survival and quality of life are significantly better compared to dialysis patients, transplant recipients nevertheless have a significantly higher cardiovascular morbidity and mortality than healthy people. One recently published study [1] shows current data and derives important conclusions for further long-term improvements in outcomes after kidney transplantation – a highly topical issue, especially for cost reasons and in the event of organ or donor scarcity.

[PRESSWIRE] Parma – 10 April, 2019 -- Chronic kidney disease (CKD) is increasingly recognized as a systemic condition. It also impacts upon other organ systems and in recent years much attention has focussed specifically on the link between the kidneys and the heart. There is also an association between brain dysfunction and kidney disease; new data shows that even mild CKD correlates with impairment of cognitive function. A new review by Professor Giovambattista Capasso summarizes the current evidence in this field.